STOCK TITAN

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)

Psyence Biomedical (Nasdaq: PBM) has completed the acquisition of Psyence Group's 11.13% stake in PsyLabs, a private company specializing in psychedelic APIs and extracts production. The deal involves a debt-for-equity swap where Psyence Biomed issued 845,394 common shares at $0.50 per share to Psyence Group. PsyLabs has granted Psyence Biomed an exclusive, worldwide, royalty-bearing IP license to supply pharmaceutical-grade, EU GMP nature-derived psilocybin for potential treatment of Alcohol Use Disorder and other Substance Use Disorders. The agreement includes a 'make whole payment' provision if share prices fall below $0.50 by January 15, 2025.

Psyence Biomedical (Nasdaq: PBM) ha completato l'acquisizione del 11,13% di Psyence Group in PsyLabs, un'azienda privata specializzata nella produzione di API e estratti psichedelici. L'accordo prevede uno scambio di debito per equità in cui Psyence Biomed ha emesso 845.394 azioni ordinarie a 0,50 dollari per azione a Psyence Group. PsyLabs ha concesso a Psyence Biomed una licenza esclusiva, mondiale e retribuita di proprietà intellettuale per fornire psilocibina di origine naturale di grado farmaceutico, conforme alle normative UE GMP, per il potenziale trattamento del Disturbo da Uso di Alcol e di altri Disturbi da Uso di Sostanze. L'accordo include una clausola di 'pagamento di compensazione' se il prezzo delle azioni scende sotto 0,50 dollari entro il 15 gennaio 2025.

Psyence Biomedical (Nasdaq: PBM) ha completado la adquisición del 11,13% de participación de Psyence Group en PsyLabs, una empresa privada especializada en la producción de API y extractos psicodélicos. El acuerdo implica un intercambio de deuda por acciones donde Psyence Biomed emitió 845,394 acciones ordinarias a 0,50 dólares por acción a Psyence Group. PsyLabs ha otorgado a Psyence Biomed una licencia exclusiva y mundial de propiedad intelectual, sujeta a regalías, para suministrar psilocibina de origen natural de grado farmacéutico, conforme a la normativa GMP de la UE, para el posible tratamiento del Trastorno por Consumo de Alcohol y otros Trastornos por Uso de Sustancias. El acuerdo incluye una disposición de 'pago de compensación' si los precios de las acciones caen por debajo de 0,50 dólares para el 15 de enero de 2025.

사이언스 바이오메디컬 (Nasdaq: PBM)는 사이언스 그룹의 PsyLabs에 대한 11.13% 지분 인수를 완료했습니다. PsyLabs는 환각제 API 및 추출물 생산을 전문으로 하는 개인 회사입니다. 이 거래에서는 Psyence Biomed가 Psyence Group에 주당 0.50달러로 845,394주를 발행하는 부채-자본 교환이 포함됩니다. PsyLabs는 Psyence Biomed에 알코올 사용 장애 및 기타 물질 사용 장애의 잠재적 치료를 위한 제약 등급, EU GMP 기준의 자연 유래 실로시빈을 공급할 수 있는 독점적이며 전 세계적으로 로열티가 붙은 지적 재산권 라이센스를 부여했습니다. 계약에는 주가가 2025년 1월 15일까지 0.50달러 이하로 떨어지면 '메이크 홀 페이먼트' 조항이 포함되어 있습니다.

Psyence Biomedical (Nasdaq: PBM) a finalisé l'acquisition de 11,13 % de participation de Psyence Group dans PsyLabs, une entreprise privée spécialisée dans la production d'APIs et d'extraits psychédéliques. L'accord implique un échange de dette contre capitaux propres où Psyence Biomed a émis 845 394 actions ordinaires au prix de 0,50 $ par action à Psyence Group. PsyLabs a accordé à Psyence Biomed une licence exclusive, mondiale et rémunérée de droits de propriété intellectuelle pour fournir de la psilocybine d'origine naturelle de qualité pharmaceutique, conforme aux normes GMP de l'UE, potentiellement pour le traitement du trouble de l'usage d'alcool et d'autres troubles liés à l'usage de substances. L'accord comprend une disposition de 'paiement de rattrapage' si le prix des actions tombe en dessous de 0,50 $ d'ici le 15 janvier 2025.

Psyence Biomedical (Nasdaq: PBM) hat den Erwerb von 11,13% der Anteile der Psyence Group an PsyLabs, einem privaten Unternehmen, das sich auf die Produktion von psychoaktiven APIs und Extrakten spezialisiert hat, abgeschlossen. Der Deal beinhaltet einen Schuld-gegen-Eigenkapital-Tausch, bei dem Psyence Biomed 845.394 Aktien zu je 0,50 Dollar an die Psyence Group ausgab. PsyLabs hat Psyence Biomed eine exklusive, weltweite und royaltiespflichtige Lizenz für das geistige Eigentum gewährt, um pharmazeutisch qualitativ hochwertige, nach EU GMP-Standards hergestellte, aus natürlichen Quellen stammende Psilocybin für eine mögliche Behandlung von Alkoholgebrauchsstörungen und anderen Substanzgebrauchsstörungen zu liefern. Die Vereinbarung umfasst eine 'Entschädigungszahlung'-Bestimmung, falls die Aktienpreise bis zum 15. Januar 2025 unter 0,50 Dollar fallen.

Positive
  • Acquisition provides vertical integration in psychedelic therapeutics development
  • Secured exclusive worldwide licensing agreement for pharmaceutical-grade psilocybin
  • Strategic partnership enables development of treatments for AUD and SUDs
Negative
  • Potential dilution from issuance of 845,394 new common shares
  • Risk of additional dilution or cash payment if share price falls below $0.50
  • Company taking on debt obligations through debt-for-equity swap

Insights

This strategic acquisition strengthens Psyence Biomedical's vertical integration in the psychedelics space. The deal structure includes an 11.13% stake acquisition in PsyLabs through a debt-for-equity swap involving 845,394 shares at $0.50 per share. The arrangement includes a 'make whole' provision protecting against potential share price decline by January 2025.

The partnership grants PBM exclusive worldwide rights to PsyLabs' pharmaceutical-grade psilocybin, positioning them uniquely in the growing mental health therapeutics market. This vertical integration could reduce costs and increase control over their supply chain, though investors should note the early-stage nature of their clinical programs for Alcohol Use Disorder and other substance use treatments.

The transaction's structure reveals careful consideration of regulatory compliance and shareholder interests. Key legal aspects include:

  • Registration requirements for share resale within 60 days
  • Board approval with appropriate director recusals
  • Expedited closing process with business justification
The exclusive licensing agreement for EU GMP-compliant psychedelics provides strong intellectual property protection, though success depends on future regulatory approvals and clinical outcomes.

PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being

Psyence Biomedical has issued common shares to Psyence Group pursuant to a debt-for-equity swap agreement

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the successful closing of its previously announced acquisition of Psyence Group's 11.13% stake in privately held PsyLabs.   

PsyLabs is focused on the cultivation and production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development. As previously announced, Psyence Biomed and PsyLabs have an existing strategic partnership whereby PsyLabs has granted Psyence Biomed a worldwide, exclusive, royalty-bearing IP licensing agreement to supply pharmaceutical-grade, EU GMP nature-derived (non-synthetic) psilocybin to be evaluated in future clinical trials as a potential treatment for Alcohol Use Disorder (AUD) and other Substance Use Disorders (SUDs) and for commercialization of the licensed product.

"We are very pleased to have acquired a direct interest in PsyLabs through this acquisition and intend to capitalize on the benefits of being one of the world’s few vertically integrated developers of psychedelic-based regulatory-approved therapeutics,” said Dr. Neil Maresky, Chief Executive Officer of Psyence Biomed.

Tony Budden, Chief Executive Officer of PsyLabs, said, “We welcome Psyence Biomed as our newest shareholder as we continue to develop our proprietary process and drug candidate, suitable for human clinical trials, in support of Psyence Biomed's pipeline of therapeutics to treat additional high-value mental health conditions, including AUD and other SUDs.”

Debt-for-Equity Swap Agreement
Psyence Group and Psyence Biomed have entered into a debt-for-equity swap agreement (the "Debt Swap Agreement"), pursuant to which Psyence Biomed has agreed to issue 845,394 Psyence Biomed common shares at a deemed price of US$0.50 per common share to Psyence Group, in exchange for the discharging of the balance of the debt repayment obligation due under a promissory note, dated January 25, 2024, issued by Psyence Biomed to Psyence Group in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024 ("Debt Swap"). In the event that the average VWAP of Psyence Biomed common shares for the ten trading days prior to January 15, 2025 is lower than US$0.50, Psyence Biomed will be required to make a "make whole payment" in cash or common shares, as set forth in the Debt Swap Agreement. Psyence Biomed has agreed to register the resale of the common shares within 60 days of the issuing of such common shares.

The Debt Swap Agreement contains customary representations, warranties and covenants of the parties. Psyence Group’s board of directors has, subject to the appropriate recusal of interested directors who are also directors of Psyence Biomed, approved the Debt Swap Agreement and no materially contrary view or abstention was expressed or made by any director in relation to the Debt Swap. Psyence Group will not file a material change report in respect of the Debt Swap at least 21 days before anticipated closing of the Debt Swap, as Psyence Group wishes to close on an expedited basis for sound business reasons.

About PsyLabs:
PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company that is federally licensed to cultivate and export psilocybin mushrooms and other psychedelic compounds, including psilocin, mescaline, ibogaine and dimethyltryptamine (DMT) to the legal medical and research markets. PsyLabs has been able to successfully demonstrate, at laboratory scale, purification of natural psilocybin to levels not seen before in the industry using its proprietary extraction and purification technologies. It is in the process of scaling to full scale commercial production of Psilocybin and into a fully formulated product, with the accompanying regulatory approvals. This work is being done in collaboration with the largest U.K. owned contract manufacturing organization.

Learn more at www.psylabs.life

Contact Information
General Information: tony@psylabs.life

About Psyence Biomed:
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the world’s few vertically integrated biopharmas with a focus on psychedelic-based pharmaceutical therapeutics. The first life science biotechnology company developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq, Psyence is initially working to address the unmet needs of patients who suffer from mental health disorders in the context of Palliative Care. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, FDA-approved, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders.

Learn more at www.psyencebiomed.com and on LinkedIn.

Contact Information for Psyence Group
Email: ir@psyence.com
Media Inquiries: media@psyence.com
General Information: info@psyence.com
Phone: +1 416-477-1708

Contact Information for Psyence Biomed
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708

Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com

Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning.

Forward-looking statements in this communication include statements regarding the benefits of the Acquisition, the advancement of PsyLabs and Psyence Biomed's respective drug development and clinical trial strategies and the progress of Psyence Biomed's existing Phase IIb clinical trial. These forward-looking statements are based on a number of assumptions, including the assumption that Psyence Biomed will be able to capitalize on the benefits of the Acquisition and that PsyLabs' drug development programme will be successfully executed.

There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: (i) the inability of Psyence Biomed to recognize the anticipated benefits of the Acquisition (ii) changes in applicable laws which may impact drug development, clinical trials and/or the conducting thereof; (iii) the inability of PsyLabs to develop a drug candidate suitable for human clinical trials; (iv) Psyence Biomed’s ability to obtain regulatory approval for the proposed product candidate, and any related restrictions or limitations of any approved products; (vi) the ability of Psyence Biomed to maintain the listing of its common shares and warrants on Nasdaq; and (vii) volatility in the price of the securities of Psyence Biomed due to a variety of factors, including changes in the competitive and highly regulated industries in which Psyence Biomed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence Biomed’s business and changes in Psyence Biomed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the final prospectus (File No. 333-282468) filed with the Securities and Exchange Commission on October 10, 2024 and other documents filed by Psyence Biomed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such information. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, neither Psyence Group nor Psyence Biomed intends to update these forward-looking statements.

Neither of the parties referenced in this news release make any medical, treatment or health benefit claims about the proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Neither of the parties referenced in this news release has conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that any of the parties referenced in this news release verified such in clinical trials or that such parties will complete such trials. If the parties cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on such parties' performance and operations.


FAQ

What percentage stake did Psyence Biomedical (PBM) acquire in PsyLabs?

Psyence Biomedical acquired an 11.13% stake in PsyLabs from Psyence Group.

How many shares did Psyence Biomedical (PBM) issue for the PsyLabs acquisition?

Psyence Biomedical issued 845,394 common shares at a deemed price of US$0.50 per share.

What is the purpose of PsyLabs' partnership with Psyence Biomedical (PBM)?

The partnership provides Psyence Biomedical with exclusive rights to supply pharmaceutical-grade psilocybin for potential treatment of Alcohol Use Disorder and other Substance Use Disorders.

When is the 'make whole payment' deadline for Psyence Biomedical (PBM)?

The make whole payment would be required if the average VWAP is below US$0.50 by January 15, 2025.

Psyence Biomedical Ltd. Common Shares

NASDAQ:PBM

PBM Rankings

PBM Latest News

PBM Stock Data

3.16M
56.32M
11.14%
5.76%
1.06%
Biotechnology
Healthcare
Link
United States of America
Toronto